Journal of Clinical Trials
Open Access
ISSN: 2167-0870
+44 1478 350008
ISSN: 2167-0870
+44 1478 350008
Malignant Pleural Mesothelioma (MPM) is a highly aggressive and almost universally fatal neoplasm with limited treatment options. The role of the programmed cell death protein 1 (PD-1) pathway has garnered attention due to its role in eliciting the immune checkpoint response of T cells, resulting in evasion of tumor cells from immune surveillance and chemotherapy resistance. Although, PD-1 checkpoint inhibitors have achieved success in various malignancies, resistance is common. Recently, the role of the gut microbiome in immunomodulation and response to cancer treatment has been recognized. We report a 70-year old female with stage 4 MPM who experienced restoration of therapeutic efficacy and prolonged survival with FMT and pembrolizumab despite prior antibiotic treatment, which is known to attenuate response.
Published Date: 2021-10-21; Received Date: 2021-09-30